title: IMMUNOGENICITY AND SAFETY OF QUINVAXEM® (DIPHTHERIA, TETANUS, WHOLE-CELL PERTUSSIS, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE) GIVEN TO VIETNAMESE INFANTS AT 2 TO 4 MONTHS OF AGE.
abstract: Vietnam plans to replace the routine childhood diphtheria, pertussis and tetanus combination (DPT) vaccine with a pentavalent vaccine. The present study was performed to assess the immunogenicity and safety of the combined diphtheria, tetanus, whole-cell pertussis, hepatitis B (HepB), and Haemophilus influenzae type b (Hib) (DTwP-HepB-Hib) Quinvaxem® vaccine in children. A total of 131 infants received the Quinvaxem® vaccine at 2, 3 and 4 months. Antibody levels were measured at baseline, at one month after the third injection and one year after the first injection. Seroprotection rates were high for each vaccine antigen at one month after the third dose: 93.1% for diphtheria, 98.5% for tetanus, 99.2% for pertussis (seroconversion rate), 93.1% for HepB, and 100% for Hib (anti-PRP ≥ 0.15 µg/ml). The rate of children with protective antibodies persisting at one year after the first dose was 88.4% for diphtheria, 49.6% for pertussis, 82.2% for tetanus, 76.7% for HepB and 97.7% for Hib (anti-PRP ≥ 0.15 µg/ml). The Quinvaxem® vaccine was well tolerated and has a low rate of adverse events. Quinvaxem® given at 2, 3 and 4 months of age was immunogenic and safe for primary immunization among infants in Vietnam.
authors: Tran Ngoc
authors: TN
authors: Huu
authors: Nguyen Thi Minh
authors: NT
authors: Phuong
authors: Nguyen Trong
authors: NT
authors: Toan
authors: Ho Vinh
authors: HV
authors: Thang
mesh_terms: D000855:Anorexia / Q000139:chemically induced; D016667:Bacterial Capsules / Q000276:immunology*; D003967:Diarrhea / Q000139:chemically induced; D004165:Diphtheria / Q000517:prevention & control*; D004168:Diphtheria Toxoid / Q000009:adverse effects / Q000276:immunology*; D004338:Drug Combinations; D005260:Female; D005334:Fever / Q000139:chemically induced; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000276:immunology*; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007223:Infant; D007508:Irritable Mood; D008297:Male; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D013742:Tetanus / Q000517:prevention & control*; D013745:Tetanus Toxoid / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D014744:Vietnam; D014917:Whooping Cough / Q000517:prevention & control*
chemical_list: D004168:Diphtheria Toxoid; D004338:Drug Combinations; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D017325:Hepatitis B Vaccines; D010567:Pertussis Vaccine; D013745:Tetanus Toxoid